SCLPScancell Holdings plc
9.500GBP-1.04%Mkt Cap: 126.45M $P/E:

Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phas…

Key Statistics

Company
Market Cap126.45M $
Enterprise Value136.21M $
Revenue (TTM)6.04M $
Gross Profit5.74M $
Net Income (TTM)-7.07M $
Revenue/Share0.0064 USD
Last Price9.500 GBP
Fiscal Year EndApr 2025
MR QuarterOct 2025
Employees60
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN
Valuation
P/E (Trailing)
P/E (Forward)-8.83
PEG
EV/EBITDA-8.19
EV/Revenue22.54
P/S21.62
P/B-11.92
EPS (TTM)-0.01
EPS (Forward)-0.01
52W Range
7.8569% of range27.00
52W High27.00 GBP
52W Low7.856 GBP
Profitability
Gross Margin94.95%
Oper. Margin-283.34%
EBITDA Margin-275.17%
Profit Margin-116.98%
ROE
ROA-52.17%
Growth
Revenue Growth
Earnings Growth
Cash Flow & Leverage
Operating CF-8.21M $
CapEx (TTM)1.97M $
FCF Margin-363.38%
FCF Yield-17.36%
Net Debt9.76M $
Net Debt/EBITDA-0.59
Balance Sheet
Debt/Equity0.00
Current Ratio0.56
Quick Ratio0.56
Book Value/Sh-0.0080 GBP
Cash/Share0.0080 GBP
Dividends
Fwd Div Rate
Trail. Div Rate0.0000 GBP
Div. Yield
5Y Avg Yield
Payout Ratio0.00%
Ex-Div Date
Pay Date
Splits
Last Split10:1
Split DateJul 26, 2011
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)25.50 GBP
Upside (mean)+168.4%
Target Range19.00 GBP32.00 GBP
GBP19.00+168.4% to meanGBP32.00
# Analysts2
Ownership
Shares Out.1.04B
Float648.13M
Insiders3.13%
Institutions38.03%
Technical
SMA 5013.85 (-31.4%)
SMA 20013.60 (-30.2%)
Beta0.69
S&P 52W Chg18.16%
Avg Vol (30d)4.47M
Avg Vol (10d)3.56M
Technical Indicators
RSI (14)24.5
MACD-1.2454
MACD Signal-1.5170
MACD Hist.+0.2716
BB Upper11.31 GBP
BB Middle9.859 GBP
BB Lower8.411 GBP
BB Width29.37%
ATR (14)0.5671 GBP
Vol Ratio (20d)1.21x